Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Asymptomatic primary hyperparathyroidism: a commentary on the revised guidelines.

Literature DB >> 19546049

Asymptomatic primary hyperparathyroidism: a commentary on the revised guidelines.

Aliya A Khan¹, John P Bilezikian, John T Potts.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Year: 2009 PMID： 19546049 PMCID： PMC3115761 DOI： 10.4158/EP09162.CO

Source DB: PubMed Journal: Endocr Pract ISSN： 1530-891X Impact factor: 3.443

× No keyword cloud information.

21 in total

1. Age as a criterion for surgery in primary hyperparathyroidism.

Authors: Shonni J Silverberg; Ijeoma Brown; John P Bilezikian
Journal: Am J Med Date: 2002-12-01 Impact factor: 4.965

2. Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism.

Authors: D Sudhaker Rao; Evelyn R Phillips; George W Divine; Gary B Talpos
Journal: J Clin Endocrinol Metab Date: 2004-11 Impact factor: 5.958

Review 3. Surgery for asymptomatic primary hyperparathyroidism: proceedings of the third international workshop.

Authors: Robert Udelsman; Janice L Pasieka; Cord Sturgeon; J E M Young; Orlo H Clark
Journal: J Clin Endocrinol Metab Date: 2009-02 Impact factor: 5.958

Review 4. Fracture risk in primary hyperparathyroidism.

Authors: Sundeep Khosla; Joseph Melton
Journal: J Bone Miner Res Date: 2002-11 Impact factor: 6.741

Review 5. Primary hyperparathyroidism and the kidney: biochemical and clinical spectrum.

Authors: Munro Peacock
Journal: J Bone Miner Res Date: 2002-11 Impact factor: 6.741

6. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism.

Authors: Munro Peacock; John P Bilezikian; Preston S Klassen; Matthew D Guo; Stewart A Turner; Dolores Shoback
Journal: J Clin Endocrinol Metab Date: 2004-11-02 Impact factor: 5.958

7. Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency.

Authors: Andrew Grey; Jenny Lucas; Anne Horne; Greg Gamble; James S Davidson; Ian R Reid
Journal: J Clin Endocrinol Metab Date: 2005-01-11 Impact factor: 5.958

8. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial.

Authors: Aliya A Khan; John P Bilezikian; Annie W C Kung; Mustafa M Ahmed; Sacha J Dubois; Andrew Y Y Ho; Debra Schussheim; Mishaela R Rubin; Atif M Shaikh; Shonni J Silverberg; Timothy I Standish; Zareen Syed; Zeba A Syed
Journal: J Clin Endocrinol Metab Date: 2004-07 Impact factor: 5.958

9. Skeletal disease in primary hyperparathyroidism.

Authors: S J Silverberg; E Shane; L de la Cruz; D W Dempster; F Feldman; D Seldin; T P Jacobs; E S Siris; M Cafferty; M V Parisien
Journal: J Bone Miner Res Date: 1989-06 Impact factor: 6.741

Review 10. Medical management of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop.

Authors: Aliya Khan; Andrew Grey; Dolores Shoback
Journal: J Clin Endocrinol Metab Date: 2009-02 Impact factor: 5.958

3 in total